Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Ethics of Stem Cell Research (Stanford Encyclopedia of …
Posted: October 6, 2015 at 6:50 am
Posted in Indiana Stem Cells
Comments Off on Ethics of Stem Cell Research (Stanford Encyclopedia of …
Biomedical Sciences Graduate Program | Epigenetics
Posted: October 6, 2015 at 6:47 am
Aggregates of the SAGA protein Ataxin-7 in Spinocerebellar Ataxia-7 astrocytes. Courtesy of Sean McCullough, graduate student in Dr. Patrick Grant's laboratory.
Research in Epigenetics at UVA focuses on the study of heritable changes in phenotype and gene function that are not caused by direct alterations in DNA sequence.
DNA in eukaryotic cells is packaged into chromatin by histone proteins. DNA-driven cellular processes such as gene expression require alteration of chromatin structure to access this packaged DNA. Epigenetic changes, including chromatin remodeling, histone exchange, or chemical modification of histone proteins, affect access to chromatin DNA. Modifications to the chromatin through processes such as DNA methylation and histone acetylation are being increasingly appreciated as key determinants of cellular phenotype. Epigenetic chromatin modification is also influenced by environmental factors and can be stably transmitted across generations.
Improved understanding of epigenetic processes is producing exciting advances in cancer detection and treatment. For example, epigenetic profiles can improve cancer detection, and new anti-cancer drugs target the chromatin modifying machinery.
The UVA epigenetics research groups utilize model organisms, mammalian cells and human-derived samples in their studies. A variety of experimental approaches, including biochemistry, genetics, genome-wide analysis and bioinformatics, and behavioral studies are being applied to study epigenetic mechanisms and changes associated with human disease.
Continue reading here:
Biomedical Sciences Graduate Program | Epigenetics
Posted in Epigenetics
Comments Off on Biomedical Sciences Graduate Program | Epigenetics
Stem cell research blooms at Yale and in Connecticut
Posted: October 5, 2015 at 4:48 pm
Eight years ago, Dr. Diane Krause was one of only two scientists at the Yale School of Medicine whose work was specifically focused on stem cells.
Today, more than 70 Yale faculty members are involved in some form of stem cell research, which since 2007 has been supported at Yale by more than $230 million in state and federal grants and funding foundations. Yale stem cell researchers have published 472 papers exploring a host of medical and scientific questions, from the origins of leukemia to the molecular basis of hair growth.
This field has grown more quickly than any of us could have envisioned, said Krause, professor of laboratory medicine, cell biology, and pathology, and since 2006 associate director of the Yale Stem Cell Center.
On Wednesday April 3, Krause will join more than 430 registrants and Governor Dannel Malloy in celebrating Connecticuts successful discoveries at the 2013 StemConn scientific symposium at the Omni Hotel in New Haven. Held every other year, the gathering will be the largest since the conference began in 2007 an outgrowth of the establishment in 2005 of the Connecticut Stem Cell Research program by the state legislature.
The success of stem cell research at Yale, as well as the University of Connecticut and Wesleyan University, is directly attributable to the programs $100 million in grants promised to state researchers over 10 years.
The states contribution has been critical to this growth and continues to be, Krause said. Every dollar the state has contributed has led to $4 more dollars in additional research funding.
The existence of the fund was a major factor in the recruitment internationally renowned stem cell biologist Haifan Lin to head the Yale Stem Cell Center. Members of the center have submitted over 130 patent applications and 26 intellectual property licenses.
The research funding program, created in response to a ban on federal funding for research using embryonic stem cells by President George W. Bush, has taken on even more importance now that scientists have discovered how to create pluripotent stem cells from an individuals own cells, notes Krause. The breakthrough holds the promised of individualized patient-specific therapy for a host of diseases.
The funding has also helped to recruit and jumpstart the careers of young scientists at Yale such as Jun Lu, whose work on how blood cells regenerate promises to help patients to better tolerate chemotherapy, and Valerie Horsley, whose work with skin stem cells has applications for wound healing and even hair growth. Scientists at Yale are researching the use of stem cells for treating diabetes and Parkinsons disease; repairing spinal cord injuries; building blood vessels to treat congenital heart defects; creating living, growing blood vessels from scratch; and even rebuilding a heart.
Original post:
Stem cell research blooms at Yale and in Connecticut
Posted in Connecticut Stem Cells
Comments Off on Stem cell research blooms at Yale and in Connecticut
STEM CELL TECHNOLOGIST with Yale-New Haven Hospital | 31281935
Posted: October 5, 2015 at 4:48 pm
Overview To be part of our organization, every employee should understand and share in the YNHHS Vision, support our Mission, and live our Values. These values-integrity, patient-centered, respect, accountability, and compassion-must guide what we do, as individuals and professionals, every day.
Under the direction of the Laboratory Manager, Stem Cell Specialist, and Assistant Chief Technologists, demonstrates ability to perform a wide variety of routine and some special technical procedures in the Stem Cell Laboratory. Demonstrates good time management and organizational skills. Interprets data based on knowledge and experience. Evaluates, troubleshoots and solves routine problems. Participates in quality control, quality assurance, and equipment maintenance programs in the laboratory.
EEO/AA Minority/Female/Disability/Veteran
Responsibilities
Qualifications EDUCATION
Education: BS Degree in a Biological Science or equivalent required.
EXPERIENCE
One to two years of relevant clinical or research laboratory experience required. Previous laboratory experience in the cell therapy field preferred.
SPECIAL SKILLS
Knowledge of stem cell regulation and accreditation requirements preferred. Familiarity with personal computer (Excel, Word) desired. Excellent interpersonal, verbal and written communication skills to interact with clinical trial sponsors and other hospital staff required. Must have excellent organizational skills.
Company Description:
Yale-New Haven Hospital is a destination hospital for patients from around the corner, around the country, and around the world. As a Magnet-recognized*, tertiary medical center, with 1,500+ beds, we are the 4th largest hospital in the country, with two acute care campuses and three emergency departments, including a Level I trauma center. We're ranked as one of "America's Best Hospitals" by U.S. News & World Report, which is a testament to the unrivaled expertise, compassion and character of our staff, and as the primary teaching facility for Yale Schools of Medicine and Nursing, we are nationally recognized for our commitment to teaching and clinical research.
Located on the Connecticut shoreline, Yale-New Haven Hospital includes Smilow Cancer Hospital at Yale-New Haven, Yale-New Haven Children's Hospital and Yale-New Haven Psychiatric Hospital.
*Yale-New Haven Hospital's York Street campus and associated ambulatory sites are Magnet-designated by the ANCC.
More:
STEM CELL TECHNOLOGIST with Yale-New Haven Hospital | 31281935
Posted in Connecticut Stem Cells
Comments Off on STEM CELL TECHNOLOGIST with Yale-New Haven Hospital | 31281935
NeoStem Oncology, LLC: Private Company Information …
Posted: October 5, 2015 at 4:48 pm
October 05, 2015 4:48 PM ET
NeoStem Oncology, LLC discovers, produces, and supplies human cell populations for research, diagnostic, clinical, and therapeutic applications. The company offers stem cell media, such as serum-free media for propagation of human embryonic stem cell (hESC); serum-free media for propagation of human myoblasts; serum-free media formulation to propagate hESC and bias their differentiation to ectodermal lineages; and products for laboratory research purposes. The company also provides human motor neuron progenitors, human cardiac progentior cells, and human neuronal progentior cells for screening and predictive toxicology applications, which are derived from human embryonic stem cells. In addit...
NeoStem Oncology, LLC discovers, produces, and supplies human cell populations for research, diagnostic, clinical, and therapeutic applications. The company offers stem cell media, such as serum-free media for propagation of human embryonic stem cell (hESC); serum-free media for propagation of human myoblasts; serum-free media formulation to propagate hESC and bias their differentiation to ectodermal lineages; and products for laboratory research purposes. The company also provides human motor neuron progenitors, human cardiac progentior cells, and human neuronal progentior cells for screening and predictive toxicology applications, which are derived from human embryonic stem cells. In addition, it offers cell transplant solution, an injectable solution for cell suspensions. NeoStem Oncology, LLC was formerly known as California Stem Cell, Inc. and changed its name to NeoStem Oncology, LLC in May 2014. The company was founded in 2005 and is based in Irvine, California. As of May 8, 2014, NeoStem Oncology, LLC operates as a subsidiary of Caladrius Biosciences, Inc.
5251 California Avenue
Suite 150
Irvine, CA92617
United States
Founded in 2005
Chairman of The Scientific Advisory Board, Chief Executive Officer, and President
Vice President of Research and Development
Compensation as of Fiscal Year 2015.
Neostem, Inc., California Stem Cell, Inc. - M&A Call
Apr 11 14
To discuss the definitive agreement to acquire California Stem Cell, Inc
U.S. Food and Drug Administration Approves California Stem Cell, Inc.'s Phase II Cancer Stem Cell Clinical Trial for Ovarian Cancer
Feb 18 14
California Stem Cell, Inc. announced that the U.S. Food and Drug Administration has approved the company's application to begin a Phase II clinical trial exploring the potential of a patient specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer. The randomized, double blind study is the company's second cancer therapy approved for clinical trials by the FDA, bolstering its platform approach to treating late stage solid-tumor cancers. The company's patient specific approach to treating metastatic melanoma, recently approved to begin a Phase III trial, provided sufficient safety data to proceed directly to a Phase II study in ovarian cancer. The study design randomizes an estimated 99 adult female patients to two treatment arms. The treatment group will receive Ovapuldencel-T, which is a combination of autologous dendritic cells loaded with irradiated autologous tumor cells in GM-CSF. Ovapuldencel-T is created by first isolating cancer stem cells from the patient's resected tumor sample, then enriching, inactivating and combining these cells with dendritic cells or antigen presenting immune cells which are harvested from the patient's blood. The control group will receive the MC treatment, harvested from the patient's blood combined with GM-CSF, granulocyte macrophage colony stimulating factor, a white blood cell growth factor. The trial design calls for both groups to receive subcutaneous injections of their respective treatment weekly for three consecutive weeks, then monthly for the following five months. The trial is expected to last approximately sixty months, including enrollment, treatment, and long term patient follow-up.
California Stem Cell, Inc. Presents at 9th Annual New York Stem Cell Summit, Feb-18-2014 11:00 AM
Jan 25 14
California Stem Cell, Inc. Presents at 9th Annual New York Stem Cell Summit, Feb-18-2014 11:00 AM. Venue: The Convene, Downtown, 32 Old Slip (between Water St. and FDR), New York, NY 10005, United States. Speakers: Hans S. Keirstead, Chairman of the Scientific Advisory Board.
Visit link:
NeoStem Oncology, LLC: Private Company Information ...
Posted in California Stem Cells
Comments Off on NeoStem Oncology, LLC: Private Company Information …
HCG Diet Plan | Drops | HCG 1234 | Injections for …
Posted: October 5, 2015 at 4:47 pm
Posted in HCG Diet
Comments Off on HCG Diet Plan | Drops | HCG 1234 | Injections for …
Buy HCG Diet Drops | HCG Activate
Posted: October 5, 2015 at 4:47 pm
Fox News, ABC, Women's Health, Men's Health and celebrity doctor Dr. Oz have raved about the HCG diet drops and their ability to melt off pounds of fat within a short time. Despite what you think, their claims arent just some marketing gimmick.
HCG (human chorionic gonadotropin) is a natural hormone usually produced by women when pregnant. It targets the hypothalamus, prompting it to utilize stored fat rather than food for producing energy. As a result, it reduces your appetite. Studies show that HCG reduces feelings of hunger, allowing individuals to eat very little comfortably. This explains why pregnant women experience nausea during the early stages of their pregnancy and lose their appetite as a result.
Another effect of HCG is the production of more hormones in the body. In most cases, obesity is the result of hormone deficiency or imbalance. Whether its your thyroid or menopause thats responsible, 10-15 drops a day will make you healthier on the inside and leaner on the outside.
Having HCG surging through your veins will also protect you from the main side effect of a low calorie diet such as the 500, 800 or 1,200 calorie protocol: muscle loss. Your muscles wont waste away because youre eating less. In fact, because of its fat burning properties, HCG will empower you to work out more or grow more active to build your muscles. Therefore, as stronger muscles allow better metabolism, youll be able to maintain your weight loss long after you stop dieting. You also want to make sure you confidently buy HCG diet drops from a trusted source like HCG Activate.
In short, HCG Diet Drops combined with a low calorie protocol will melt those extra inches away, keep them off, and ensure your health for years to come.
Read more:
Buy HCG Diet Drops | HCG Activate
Posted in HCG Diet
Comments Off on Buy HCG Diet Drops | HCG Activate
Behavioral epigenetics – Wikipedia, the free encyclopedia
Posted: October 5, 2015 at 4:45 pm
Posted in Epigenetics
Comments Off on Behavioral epigenetics – Wikipedia, the free encyclopedia
Faculty & Staff | Directory | Medical Partnership
Posted: October 5, 2015 at 4:44 pm
Dr. Melissa B. Davis is a native of Albany, Georgia. Her interest in the field of genetics was sparked by a summer research program at The Ohio State University, where she conducted spinal cord regeneration studies in the Tassava Lab in the department of molecular genetics. After her undergraduate studies, Dr. Davis completed her Ph.D. in the department of genetics at UGA in 2003.
Dr. Melissa B. Davis completed a postdoc fellowship with Dr. Kevin White at Yale School of Medicine in 2006. While there, she also served as a teaching coordinator of the Yale School of Medicine Summer Medical Education Program for visiting undergraduates, aiding in the pre-med training of over 300 undergraduates. She completed additional postdoctoral training in functional genomics and cancer disparities at the University of Chicago in 2009. Her work became part of the international ModEnCODE project, to delineate the regulatory elements of genes across the Drosophilia genome. In addition, Dr. Davis was a postdoctoral scholar at the University of Chicago's Center for Interdisciplinary Health Disparities Research. She began training with the center to conduct breast cancer disparities research under the guidance of Dr. Olufunmilayo Olopade, one of the world's leaders in global health and breast cancer disparities research. Her work with the center includes identification of associations of epigenetic cofactors with breast cancer subtypes that are predominantly found in women of African descent.
Following her postdoctoral training, Davis joined the inaugural GRU/UGA Medical Partnership faculty in 2009 as a genetics professor. Currently she is a tenure-track faculty member with the UGA Department of Genetics and serves in a dual role with the Medical Partnership. Her lab conducts research concerned with the molecular and environmental factors that impact the etiology of breast cancer subtypes. She is also investigating the role of ancestral genetics on predisposition to these tumor types and/or oncogene expression and function. For this work, Davis is collaborating with researchers in the UGA College of Public Health to uncover the environmental factors that impact epigenetic regulation of key metabolism, immunity, and cancer genes.
Read more:
Faculty & Staff | Directory | Medical Partnership
Posted in Genetics
Comments Off on Faculty & Staff | Directory | Medical Partnership
Going viral: chimeric antigen receptor T-cell therapy for …
Posted: October 4, 2015 at 11:41 pm
On July 1, 2014, the United States Food and Drug Administration granted 'breakthrough therapy' designation to CTL019, the anti-CD19 chimeric antigen receptor T-cell therapy developed at the University of Pennsylvania. This is the first personalized cellular therapy for cancer to be so designated and occurred 25 years after the first publication describing genetic redirection of T cells to a surface antigen of choice. The peer-reviewed literature currently contains the outcomes of more than 100 patients treated on clinical trials of anti-CD19 redirected T cells, and preliminary results on many more patients have been presented. At last count almost 30 clinical trials targeting CD19 were actively recruiting patients in North America, Europe, and Asia. Patients with high-risk B-cell malignancies therefore represent the first beneficiaries of an exciting and potent new treatment modality that harnesses the power of the immune system as never before. A handful of trials are targeting non-CD19 hematological and solid malignancies and represent the vanguard of enormous preclinical efforts to develop CAR T-cell therapy beyond B-cell malignancies. In this review, we explain the concept of chimeric antigen receptor gene-modified T cells, describe the extant results in hematologic malignancies, and share our outlook on where this modality is likely to head in the near future.
2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
See the original post:
Going viral: chimeric antigen receptor T-cell therapy for ...
Posted in Cell Therapy
Comments Off on Going viral: chimeric antigen receptor T-cell therapy for …